Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT )

125.04 -1.23 (-0.97%)
Streaming Delayed Price Updated: 3:31 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
From Sarepta Therapeutics, Inc.
Via Business Wire
In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
2 Magnificent Growth Stocks to Buy With $500
No need to break the bank to invest in promising stocks. 
Via The Motley Fool
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Exposures Product Safety
Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
Via Benzinga
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Bad news for one player does not always equal good news for another. 
Via The Motley Fool
Decoding Bearish Analog And The Warning Signs You Can't Ignore
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy 
Via MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy. 
Via Benzinga
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
From Sarepta Therapeutics, Inc.
Via Business Wire
MarketBeat Week in Review: 1/22 - 1/26
Markets continued to push to new all-time highs, setting the stage for big tech earnings, which will happen next week; here are the top stories from this week. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Got $3,000? 3 Growth Stocks to Double Up On Right Now
There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important. 
Via The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
It's always tough to be compared to a giant. 
Via The Motley Fool
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
Via MarketBeat
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
One pundit feels there is solid potential in one of the company's more recently approved drugs. 
Via The Motley Fool
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product  
Via Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram. 
Via InvestorPlace
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Last year wasn't great for either stock, but that's no reason to ignore them. 
Via The Motley Fool
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.